Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis on Early Detection of Lung Cancer by PET/CT Scan

  • Wang, Huo-Qiang (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zhao, Long (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zhao, Juan (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Wang, Qiang (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This systemic analysis was conducted to to evaluate the application value of positron emission tomography/computed tomography (PET/CT) in early diagnosis of lung cancer. Methods: Clinical studies evaluating the application value of PET/CT for patients underwent PET/CT imaging. The histological diagnosis served as the standard of truth. Results: Four clinical studies which including 1330 patients with pulmonary spaceoccupying lesions were considered eligible for inclusion. Systemic analysis suggested that, in all 1330 patients, pooled sensitivity was 98.7% (1313.2/1330) and specificity was 58.2%(276.85/476). Conclusion: This systemic analysis suggests that integrated PET/CT imaging provides high sensitivity, and reasonably high specificity, and could be applied for early diagnosis of lung cancer.

Keywords

References

  1. Balogova S, Huchet V, Kerrou K, et al (2010). Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun, 31, 389-97.
  2. Changlai SP, Tsai SC, Chou MC, et al (2001). Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep, 8, 337-9.
  3. Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
  4. Demura Y, Tsuchida T, Ishizaki T, et al (2003). 18F-FDG accumulation with PET for differentiation between benign and malignant nodules in the thorax. J Nucl Med, 44, 540-8.
  5. Fei ZH, Yao CY, Yang XL, et al (2013). Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9. https://doi.org/10.7314/APJCP.2013.14.9.5293
  6. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
  7. Hou ZB, Lu KJ, Wu XL, et al (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment.Asian Pac J Cancer Prev, 15, 1767-9 https://doi.org/10.7314/APJCP.2014.15.4.1767
  8. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  9. Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
  10. Kaira K, Yamamoto N, Endo M, et al (2014). 18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. Oncol Rep, 31, 209-215.
  11. Lee TS, Ahn SH, Moon BS, et al (2009). Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol, 36, 681-686. https://doi.org/10.1016/j.nucmedbio.2009.03.009
  12. Liu FL, Hong QY, Shi HC, et al (2013). Value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in early diagnosis of lung cancer.Zhonghua Yi Xue Za Zhi, 93, 3019-22.
  13. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  14. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
  15. Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection ($Yadanzi^{(R)}$) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. https://doi.org/10.7314/APJCP.2013.14.8.4791
  16. Minamimoto R, Senda M, Jinnouchi S, et al (2014). Detection of lung cancer by FDG-PET cancer screening program: a nationwide Japanese survey. Anticancer Res, 34, 183-9.
  17. Shreve PD, Anzai Y, Wahl RL (1999). Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics, 19, 61-77. https://doi.org/10.1148/radiographics.19.1.g99ja0761
  18. Wang ZX, Zhang B, Wu YW, et al (2011). The clinic value of (18)F-FDG PET/CT imaging in differentiation of malignant from benign disease in lung. Zhonghua Yi Xue Za Zhi, 91, 2456-8.
  19. Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. https://doi.org/10.7314/APJCP.2013.14.8.4801